

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

NCT07039578

Status	RECRUITING
Phase	Phase 2
Sponsor	Keymed Biosciences Co.Ltd
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (8)

- Voluntary provision of written informed consent and ability to comply with protocol requirements.
- Age ≥18 years, any gender.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
- Confirmed diagnosis of primary light-chain (AL) amyloidosis.
- Relapsed or refractory primary AL amyloidosis.

... and 3 more (see full listing online)

Exclusion (5)

- Current or prior diagnosis of multiple myeloma.
- Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.
- Clinically significant cardiovascular or cerebrovascular disease.
- Any active or uncontrolled infection meeting protocol-defined criteria.
- Any other condition deemed by the Investigator to preclude safe study participation.

Locations (2 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China